SCHEMBL23175233

SCHEMBL23175233

CC1(C)CNC(=O)c2cccnc2O1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
CYP1A2 P05177 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
AKR1B1 P15121 1/20 0.36
MTOR P42345 1/20 0.36
NPC1 O15118 2/20 0.35
ALDH1A1 P00352 3/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35
MCL1 Q07820 1/20 0.35
TDP2 O95551 1/20 0.34
NSD2 O96028 1/20 0.34
ABL1 P00519 1/20 0.34
PLCG1 P19174 1/20 0.34
CES1 P23141 1/20 0.34
PAX8 Q06710 1/20 0.34
RIN1 Q13671 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1694045 0.78 CNR1 (0.44) KDM4EALDH1A1GAAMAPTTDP2
SCHEMBL24251672 0.77 OTUD7B (0.37) CYP1A2SMN1; SMN2AKR1B1MTORNPC1
SCHEMBL1666910 0.76 KDM4E (0.55) KDM4ECYP1A2SMN1; SMN2MTORNPC1
SCHEMBL9550531 0.74 KDM4E (0.41) KDM4EMTORPARP10PARP11CDC7
SCHEMBL4313114 0.71 TDP1 (0.39) KDM4ECYP1A2SMN1; SMN2AKR1B1MTOR
SCHEMBL18321939 0.70 CHRNB2 (0.37) NPC1
SCHEMBL31306088 0.70 CA12 (0.33) KDM4ESMN1; SMN2AKR1B1NPC1ALDH1A1
SCHEMBL20290300 0.70 CA12 (0.33) KDM4ESMN1; SMN2AKR1B1NPC1ALDH1A1
SCHEMBL3063384 0.69 FABP6 (0.44) CYP1A2SMN1; SMN2GAATDP2NSD2
Hydrochloric Acid SCHEMBL29404790 0.69 CHRNB2 (0.36) NPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-02-15 US disclosed
US-11725001-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-08-15 US disclosed
US-20220402902-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2022-12-22 US disclosed
WO-2021066578-A1 BICYCLIC COMPOUND AND USE THEREOF 에스케이바이오팜 주식회사 2021-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402902-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 KDM4E 44/4885CYP1A2 3773/4885SMN1; SMN2 1957/4885
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 KDM4E 44/4885CYP1A2 3773/4885SMN1; SMN2 1957/4885
US-11725001-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 KDM4E 44/4885CYP1A2 3773/4885SMN1; SMN2 1957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.